Today’s A.S.H. news focussed on chronic
leukaemias:
 | BTKi Improves Disease Control in CLL After Progression on Venetoclax In this small study, patients with relapsed/refractory chronic lymphocytic leukemia who achieved prolonged or complete remission while on venetoclax had significantly longer progression-free survival on BTKi therapy. |
 |
Interim Results of Randomized Comparison of Ponatinib Starting Doses in Chronic-Phase CML Response-based ponatinib dosing demonstrated clinical benefit in patients with resistant chronic-phase chronic myeloid leukemia, according to results presented as part of the ASCO20 Virtual Scientific Program. |
 |
Demystifying PCR-Based Molecular Monitoring in CML ASH Clinical News spoke with experts about the development of PCR molecular-based testing, how it is used in CML, and how the technology is evolving. |
No comments:
Post a Comment